Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 December 2023 | Story Leonie Bolleurs | Photo Supplied
3D-Printed Sculptural Artefact
The 3D-printed sculptural artefact entered by a group of third-years from the UFS.

A group of third-year students from the UFS Department of Architecture exhibited their work at the 2023 Venice Biennale, an international architecture exhibition showcasing ground-breaking architectural work from various countries around the world.

The contributions of world-class architects, researchers, and institutions in architecture are exhibited at this exhibition. “To be featured in this exhibition means that we are recognised by the international community as one of the leading architectural learning sites in South Africa and the work being produced at the institution deserves international acclaim,” says Phadi Mabe, Lecturer in the department.

The students representing the university with Mabe and participating in this event are Anya Strydom, Yamkelwa Simelane, Jan Truter, and Khalipha Radebe.

Mabe says the artefact produced from this project is a 3D-printed sculptural device that shows the translation between sound and object and illustrates the sound data through 3D-printed forms. “The sound structures of South Africa’s languages are mapped three-dimensionally to create a visual and spatial record of language. This unique artefact demonstrates that there are uncharted terrains in architecture, suggesting alternative dimensions that can be extrapolated to show that architecture can represent the intangible” he explains.

The UFS artefact was one of six design artefacts selected for the 18th International Architecture Exhibition – La Biennale di Venezia, which opened to the public in May and closes on 26 November 2023.

Hosted by the Department of Sport, Arts and Culture, the competition involved an emphasis on students incorporating African traditional architecture into their design models.

News Archive

Nano research at the UFS opens door to smart drugs
2011-06-27

 

Prof. Lodewyk Kock, outstanding professor in our Department of Microbial, Biochemical and Food Biotechnology

Novel antifungal, anticancer and anti-malaria drugs that have been identified in the research of Prof. Lodewyk Kock, outstanding professor in the Department of Microbial, Biochemical and Food Biotechnology at our university, will be disclosed later this year at major international conferences in Asia, Europe and the USA. Prof. Kock will be the keynote speaker at these conferences. 

His presentations will be based on the department’s discovery of yeast assays linked to a new nanotechnology for medicine. The assays were recently discovered by his group and can be applied in the development of novel antifungal, anticancer and anti-malaria drugs.
 
Prof. Kock’s focused research at the university, which now also includes his novel nanotechnology for Biology, began in 1982 in collaboration with Prof. Pieter van Wyk (Centre for Microscopy). He recently collaborated with Prof. Hendrik Swart (Department of Physics).
 
Prof. Kock says the development of novel anti-malaria drugs in particular is getting attention across the world due to the high rates of morbidity and mortality caused by the disease worldwide. Approximately 225 million people are infected annually and about a million (many in Africa) die each year. “Many potential smart drugs have been identified with this research and should now be tested further,” says Kock.
  
These new drugs will be disclosed during Prof. Kock’s keynote addresses at the International Conference and Exhibition on Pharmaceutical Regulatory Affairs in Baltimore, USA, from 6 to 7 September 2011, the Medichem 2011 in Beijing, China from 9 to 11 August 2011 and the XVI Congress of European Mycologists in Greece, from 19 to 23 September 2011.

 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept